Rezultati pretraživanja
  1. Fresenius Kabi has launched into to provide greater access to important medicines in the fields of autoimmune diseases and oncology. Find out more 👉

  2. prije 19 minuta

    and announce public workshop for March 9, 2020, on a Competitive Marketplace for -

  3. prije 34 minute

    March 9 workshop: Food and Drug Administration/Federal Trade Commission Workshop on a Competitive Marketplace for Biosimilars

    Prikaži ovu nit
  4. prije 36 minuta

    guidance notice: Promotional Labeling and Advertising Considerations for Prescription Biological Reference and Biosimilar Products--Questions and Answers

    Prikaži ovu nit
  5. prije 5 sati

    5 years of in the US: what have we learned?

  6. prije 5 sati

    offer an opportunity to help reduce total biologic drug spend. They could save between $54 to $250 bn over their first 10 years on the market. According to a recent estimate, there are more than 1000 biosimilars in any stage of the pipeline

  7. 1. velj

    Experts in the field of wrap up their discussion by considering what must be done to educate pharmacists, nurses, and patients.

  8. 1. velj

    From proposed stakeholder incentives in U.S. policy to the improvement of competition in the oncology space, 2019 was an eventful year for . Via

  9. 1. velj

    With the sales growth seen so far and the likely addition of a Remicade biosimilar, Bernstein analyst Ronny Gal said "it's tough to see " Amgen 2020 biosimilar sales of less than $1.8 billion, up from $570 million in 2019.

  10. 31. sij

    How much does your state save? In 2018, generic prescription medicines saved $1.3B, and $293B for the U.S. health care system overall. Use this interactive map to see how much your state saved:

  11. 31. sij

    Will ever catch on in the ?

  12. 30. sij

    Uptake of TNFi in rheumatology has been slow.

  13. 30. sij

    According to a report by , by 2021, Ontario's biologics expenditure will likely increase to $1.4 billion for an estimated 564,672 users. See the full report here

  14. 30. sij

    Kashyap Patel, MD says that ’ safety and efficacy have already been established--what is needed is intensive education in the U.S.

  15. 29. sij

    With an average cost of 26% less than their reference products, could provide up to $150B in savings over the next decade, notes @USBiosimilar President Juliana Reed in a recent op-ed. Read more:

  16. Odgovor korisnicima i sljedećem broju korisnika:

    The other concern is would as many head-to-head studies be conducted on ? As an patient, that’s a huge concern of mine. I would want those studies to help push forward into the era of precision medicine.

  17. | on Studies in 2019 support the effectiveness and safety of nonmedical switching and the benefits of communicating information about biosimilars to patients in a positive light. Check it out at

  18. 28. sij

    have struggled to gain traction in the U.S. despite widespread adoption in Europe. Experts take recent successful launches as a positive sign for the biosimilar market overall in 2020. More:

  19. 28. sij

    Chip Davis, President & CEO of sees "fearmongering about the quality of biosimilars" perception and lobbying efforts as reasons for slow uptake in the U.S. By enacting incentives for , usage will increase.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.